Bioparin, LLC

Bioparin is an early-stage biotech company focused on bioengineering critical lifesaving anticoagulant drugs including unfractionated heparin and low molecular weight heparin. Heparin is one of the most widely used injectable anticoagulants in the United States, essential for surgeries, stroke treatments, dialysis, and other critical medical procedures. However, the current global heparin supply relies entirely on pig intestines, making it vulnerable to disease outbreaks and contamination. Bioparin aims to eliminate reliance on animal-sourced heparin by developing a synthetic variant that offers greater safety, consistency, and availability. By leveraging bioreactor technology, their innovation ensures a controlled production process, preventing critical shortages and reducing costs for healthcare providers and patients.